Discovery of the Proprotein Convertases and their Inhibitors [PDF]
, 2006 The members of the convertase family play a central role in the processing of various protein precursors ranging from hormones and growth factors to viral envelope proteins and bacterial toxins. The proteolysis of these precursors that occurs at basic residues is mediated by the proprotein convertases (PCs), namely: PC1, PC2, Furin, PACE4, PC4, PC5 and
Abdel-Majid Khatib +4 more
openaire +1 more source
Informatics in Medicine Unlocked, 2022 Hypercholesterolemia is a potential cardiovascular hazard that requires immediate therapeutic intervention. Research has shown that 3-Hydroxy-3-methylglutaryl- CoA reductase (HMG CoA reductase) and Proprotein convertase subtilisin/kexin type 9 (PCSK9 ...
Precious A. Akinnusi +8 more
doaj
Unpacking and understanding the impact of proprotein convertase subtilisin/kexin type 9 inhibitors on apolipoprotein B metabolism [PDF]
, 2017 No abstract ...
Packard, Chris J.
core +1 more source
The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9 [PDF]
Pharmacological Reviews, 2017 The secretory proprotein convertase (PC) family comprises nine members, as follows: PC1/3, PC2, furin, PC4, PC5/6, paired basic amino acid cleaving enzyme 4, PC7, subtilisin kexin isozyme 1/site 1 protease (SKI-1/S1P), and PC subtilisin/kexin type 9 (PCSK9).
Stefan Prost +4 more
openaire +2 more sources
PCSK9 induces a pro-inflammatory response in macrophages [PDF]
, 2018 Intraplaque release of inflammatory cytokines from macrophages is implicated in atherogenesis by inducing the proliferation and migration of media smooth muscle cells (SMCs). PCSK9 is present and released by SMCs within the atherosclerotic plaque but its
Adorni, Maria Pia +12 more
core +3 more sources
Effects of proprotein convertase subtilisin/kexin type-9 inhibitors on fatty liver
World Journal of Hepatology, 2020 BACKGROUND Many studies have investigated the progression of nonalcoholic fatty liver disease (NAFLD) and its predisposing risk factors, but the conclusions from these studies have been conflicting.
Muhammad Shafiq +4 more
semanticscholar +1 more source
Systematic review and network meta-analysis on the efficacy of evolocumab and other therapies for the management of lipid levels in hyperlipidemia [PDF]
, 2017 Background: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors evolocumab and alirocumab substantially reduce low‐density lipoprotein cholesterol (LDL‐C) when added to statin therapy in patients who need additional LDL‐C reduction ...
Bray, Sarah +13 more
core +1 more source
PCSK9 Levels and Metabolic Profiles in Elderly Subjects with Different Glucose Tolerance under Statin Therapy [PDF]
, 2021 Proprotein convertase subtilisin/kexin type 9 (PCSK9) degrades low-density lipoprotein cholesterol (LDL-C) receptors, and thus regulates the LDL-C levels in the circulation. Type 2 diabetics often have elevated LDL-C levels.
Auvinen, Juha +8 more
core +1 more source
Acta Pharmacologica Sinica, 2020 Hyperlipidemia (HPL) characterized by metabolic disorder of lipids and cholesterol is one of the important risk factors for cardiovascular diseases. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a potent circulating regulator of LDL through ...
Zhen-li Su +7 more
semanticscholar +1 more source
Novel Homozygous Inactivating Mutation in the PCSK1 Gene in an Infant with Congenital Malabsorptive Diarrhea. [PDF]
, 2021 Proprotein convertase 1/3 (PC1/3), encoded by the PCSK1 gene, is expressed in neuronal and (entero)endocrine cell types, where it cleaves and hence activates a number of protein precursors that play a key role in energy homeostasis.
Aerts, Laetitia +6 more
core +2 more sources